Atea Pharmaceuticals Files 8-K with Key Corporate Updates
Ticker: AVIR · Form: 8-K · Filed: Apr 17, 2025 · CIK: 1593899
| Field | Detail |
|---|---|
| Company | Atea Pharmaceuticals, Inc. (AVIR) |
| Form Type | 8-K |
| Filed Date | Apr 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, material-agreement
TL;DR
Atea Pharma 8-K dropped: new deals, exec changes, and financials filed. Check it out.
AI Summary
Atea Pharmaceuticals, Inc. filed an 8-K on April 17, 2025, reporting on April 16, 2025. The filing indicates an entry into a material definitive agreement, results of operations and financial condition, departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements, and Regulation FD disclosures. It also includes financial statements and exhibits.
Why It Matters
This 8-K filing provides crucial updates on Atea Pharmaceuticals' corporate governance, financial status, and material agreements, which are important for investors to assess the company's current standing and future direction.
Risk Assessment
Risk Level: medium — The filing covers multiple significant corporate events including executive changes and financial condition, which can introduce uncertainty and impact stock price.
Key Players & Entities
- Atea Pharmaceuticals, Inc. (company) — Registrant
- April 16, 2025 (date) — Earliest event reported
- April 17, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Boston, MA (location) — Principal executive address
FAQ
What specific material definitive agreement was entered into by Atea Pharmaceuticals?
The filing indicates an entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
What are the key items reported under 'Results of Operations and Financial Condition'?
The filing mentions reporting on 'Results of Operations and Financial Condition', but the specific financial details are not included in the provided text.
Were there any departures of directors or officers on April 16, 2025?
The filing lists 'Departure of Directors or Certain Officers' as an item reported, but does not specify if any departures occurred on April 16, 2025, or who was involved.
What is Atea Pharmaceuticals' fiscal year end?
Atea Pharmaceuticals' fiscal year ends on December 31 (1231).
What is the SEC file number for Atea Pharmaceuticals?
The SEC file number for Atea Pharmaceuticals is 001-39661.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 17, 2025 regarding Atea Pharmaceuticals, Inc. (AVIR).